Drug Development

At Usona, we continually invest in our Drug Development programs to strengthen our capabilities and extend our global reach. Usona is leveraging state-of-the art science to develop drug therapies and accompanying supportive therapeutic framework for challenging mental health conditions.

We currently have two drug development programs in the clinical stage.

Psilocybin

Usona is currently exploring the therapeutic potential of psilocybin in the treatment of major depressive disorder (MDD).

Psilocybin

5-MeO-DMT

Usona has completed the preclinical safety studies required by the US FDA and has recently been granted authorization to proceed to clinical trials in healthy volunteers.

LEARN MORE ABOUT 5-MeO-DMT